Wuxi Municipal Center for Disease Control and Prevention, Wuxi, China.
School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China.
JMIR Public Health Surveill. 2023 Mar 24;9:e43635. doi: 10.2196/43635.
BACKGROUND: Community-based organizations deliver peer-led support services to people living with HIV. Systematic reviews have found that peer-led community-based support services can improve HIV treatment outcomes; however, few studies have been implemented to evaluate its impact on mortality using long-term follow-up data. OBJECTIVE: We aimed to evaluate the associations between the receipt of peer-led community-based support services and HIV treatment outcomes and survival among people living with HIV in Wuxi, China. METHODS: We performed a propensity score-matched retrospective cohort study using data collected from the Chinese National HIV/AIDS Comprehensive Information Management System for people living with HIV in Wuxi, China, between 2006 and 2021. People living with HIV who received adjunctive peer-led community-based support for at least 6 months from a local community-based organization (exposure group) were matched to people living with HIV who only received routine clinic-based HIV care (control group). We compared the differences in HIV treatment outcomes and survival between these 2 groups using Kaplan-Meier curves. We used competing risk and Cox proportional hazards models to assess correlates of AIDS-related mortality (ARM) and all-cause mortality. We reported adjusted subdistribution hazard ratio and adjusted hazard ratio with 95% CIs. RESULTS: A total of 860 people living with HIV were included (430 in the exposure group and 430 in the control group). The exposure group was more likely to adhere to antiretroviral therapy (ART; 396/430, 92.1% vs 360/430, 83.7%; P<.001), remain retained in care 12 months after ART initiation (402/430, 93.5% vs 327/430, 76.1%; P<.001), and achieve viral suppression 9 to 24 months after ART initiation (357/381, 93.7% vs 217/243, 89.3%; P=.048) than the control group. The exposure group had significantly lower ARM (1.8 vs 7.0 per 1000 person-years; P=.01) and all-cause mortality (2.3 vs 9.3 per 1000 person-years; P=.002) and significantly higher cumulative survival rates (P=.003). The exposure group had a 72% reduction in ARM (adjusted subdistribution hazard ratio 0.28, 95% CI 0.09-0.95) and a 70% reduction in all-cause mortality (adjusted hazard ratio 0.30, 95% CI 0.11-0.82). The nonrandomized retrospective nature of our analysis prevents us from determining whether peer-led community-based support caused the observed differences in HIV treatment outcomes and survival between the exposure and control groups. CONCLUSIONS: The receipt of peer-led community-based support services correlated with significantly improved HIV treatment outcomes and survival among people living with HIV in a middle-income country in Asia. The 15-year follow-up period in this study allowed us to identify associations with survival not previously reported in the literature. Future interventional trials are needed to confirm these findings.
背景:社区组织为艾滋病毒感染者提供由同伴主导的支持服务。系统评价发现,同伴主导的社区支持服务可以改善艾滋病毒治疗效果;然而,很少有研究使用长期随访数据来评估其对死亡率的影响。
目的:我们旨在评估在中国无锡市,艾滋病毒感染者接受同伴主导的社区支持服务与艾滋病毒治疗效果和生存之间的关系。
方法:我们使用了来自中国无锡市艾滋病毒感染者国家艾滋病综合信息管理系统的数据,开展了一项倾向评分匹配的回顾性队列研究,时间范围为 2006 年至 2021 年。从当地社区组织接受至少 6 个月同伴主导的社区支持服务的艾滋病毒感染者(暴露组)与仅接受常规诊所艾滋病毒护理的艾滋病毒感染者(对照组)相匹配。我们使用 Kaplan-Meier 曲线比较了这两组之间的艾滋病毒治疗效果和生存差异。我们使用竞争风险和 Cox 比例风险模型来评估 AIDS 相关死亡率(ARM)和全因死亡率的相关因素。我们报告了调整后的亚分布风险比和调整后的风险比及其 95%置信区间。
结果:共纳入 860 名艾滋病毒感染者(暴露组 430 名,对照组 430 名)。暴露组更有可能坚持接受抗逆转录病毒治疗(ART;396/430,92.1%比 360/430,83.7%;P<.001),在 ART 启动后 12 个月内保持保留在护理中(402/430,93.5%比 327/430,76.1%;P<.001),并在 ART 启动后 9 至 24 个月内实现病毒抑制(357/381,93.7%比 217/243,89.3%;P=.048)。与对照组相比,暴露组的 ARM(每 1000 人年 1.8 比 7.0;P=.01)和全因死亡率(每 1000 人年 2.3 比 9.3;P=.002)显著较低,累积生存率显著较高(P=.003)。暴露组的 ARM 降低了 72%(调整后的亚分布风险比 0.28,95%CI 0.09-0.95),全因死亡率降低了 70%(调整后的风险比 0.30,95%CI 0.11-0.82)。我们分析的非随机回顾性性质使我们无法确定同伴主导的社区支持服务是否导致了暴露组和对照组之间观察到的艾滋病毒治疗效果和生存差异。
结论:在亚洲中等收入国家,接受同伴主导的社区支持服务与艾滋病毒感染者的治疗效果和生存显著改善相关。本研究的 15 年随访期使我们能够确定与以前文献中未报道的生存相关的因素。需要进行未来的干预性试验来证实这些发现。
Cochrane Database Syst Rev. 2022-2-1
J Int Assoc Provid AIDS Care. 2024
Health Promot Pract. 2023-1
China CDC Wkly. 2019-11